HDAC1
Histone deacetylase 1
As of the edition of 20 October 2026, HDAC1 (histone deacetylase 1, UniProt Q13547) has 6 drugs tested at it and 7 companies on the list, 3 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13547
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 20
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Lungs and airways; Urinary and reproductive; Digestive system; Nervous system
- Registered trials of its drugs
- 499
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 1 |
| Stopped | 3 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Vorinostat | Marketed | Phase 3 | Ends 2027 |
| Tucidinostat | Marketed | Phase 4 | none listed |
| Mocetinostat | Stopped | Phase 2 | none listed |
| Nanatinostat | Stopped | Phase 2 | none listed |
| MTX110 | Stopped | Phase 1 | none listed |
| Pyroxamide | Went quiet | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 1 |
| Engaged | 2 |
| Undetermined | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Merck & Co. | Route B |
| Bristol Myers Squibb | Route A |
| Viracta Therapeutics | Route A |
The other 4 companies at HDAC1
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at HDAC1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.